Achieve Life Sciences Deferred Revenue | ACHV

Deferred revenue is the amount of money or obligations that a company has received in advance for goods or services that have not yet been delivered or performed. In other words, it is income that has already been received but has not yet been recognized in accounting as revenue because the goods or services have not yet been transferred to the customer.

Features of the metric

Sources of future cash inflows
A high level of deferred revenue indicates that the company has secured future cash flows, which positively affects forecasts of its financial condition and stability.
Assessment of operational stability
Deferred revenue reflects demand for the company’s products or services and its ability to attract customers willing to pay in advance. It is one of the indicators of business stability and its competitive advantages.
Risks and obligations
Although deferred revenue indicates future inflows, it also represents obligations that the company must fulfill. If fulfilling these obligations is delayed or impossible, it can negatively impact reputation and financial results.
Analysis of liquidity and cash flow
Inflows in the form of deferred revenue improve the company’s current liquidity since the funds are already in the accounts. However, investors need to assess the ratio of deferred revenue to fulfilled obligations to understand the actual financial capabilities and risks.
Impact on company valuation
In fundamental analysis, deferred revenue is taken into account for accurate revenue and profit forecasting, especially in industries with long-term contracts or subscriptions (e.g., IT sector, services, manufacturing).

Annual Deferred Revenue Achieve Life Sciences

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008
-	-	-	-	-	-	-	-	-	-	5.04 M	-	-	-	18.3 M	10 M	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
18.3 M	5.04 M	11.1 M

Quarterly Deferred Revenue Achieve Life Sciences

2026-Q1	2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.1 M	5.04 M	5.04 M	5.04 M	5.04 M	-	-	-	-	-	-	-	-	-	9.14 M	15.4 M	17.3 M	18.3 M	18.3 M	18.3 M	18.3 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
18.3 M	2.1 M	11.4 M

Deferred Revenue of other stocks in the Biotechnology industry

Issuer	Deferred Revenue	Price	% 24h	Market Cap	Country
Celsion Corporation CLSN	500 K	-	-6.63 %	$ 13.9 M	USA
Qilian International Holding Group Limited QLI	3.14 M	-	-6.08 %	$ 184 M	China
Synthetic Biologics SYN	906 K	-	1.32 %	$ 16.2 M	USA
Dynavax Technologies Corporation DVAX	2.65 M	-	-	$ 2.02 B	USA
I-Mab IMAB	2.2 M	-	-	$ 866 M	China
BeyondSpring BYSI	1.35 M	$ 0.84	34.27 %	$ 34.5 M	USA
AgeX Therapeutics AGE	283 K	-	-10.17 %	$ 12.2 K	USA
Alexion Pharmaceuticals, Inc. ALXN	15.9 M	-	-	$ 40.3 B	USA
Genfit SA GNFT	124 K	-	2.54 %	$ 160 B	France
Cerus Corporation CERS	1.27 M	$ 2.98	4.93 %	$ 568 M	USA
Compugen Ltd. CGEN	11 M	$ 2.41	4.17 %	$ 225 M	Israel
CureVac N.V. CVAC	158 M	-	-	$ 867 M	Germany
EyeGate Pharmaceuticals, Inc. EYEG	2.69 M	-	-1.52 %	$ 24.7 M	USA
Midatech Pharma plc MTP	1.3 M	-	-18.52 %	$ 27.3 M	Britain
MorphoSys AG MOR	86.5 M	-	2.43 %	$ 254 M	Germany
Champions Oncology CSBR	8.83 M	$ 5.1	2.63 %	$ 70.5 M	USA
Affimed N.V. AFMD	55 M	-	-34.95 %	$ 21.5 M	Germany
AnPac Bio-Medical Science Co., Ltd. ANPC	4.96 M	-	-1.58 %	$ 28.1 M	China
Celyad Oncology SA CYAD	2.21 M	-	-	$ 12.5 M	Belgium
Generation Bio Co. GBIO	10.6 M	-	-	$ 344 M	USA
AnaptysBio ANAB	2.94 M	$ 58.47	4.37 %	$ 1.68 B	USA
Anika Therapeutics ANIK	24.5 K	$ 21.5	1.56 %	$ 308 M	USA
Aurinia Pharmaceuticals AUPH	3.72 M	$ 15.47	1.91 %	$ 2.08 B	Canada
GlycoMimetics GLYC	4.16 M	-	9357.83 %	$ 1.01 B	USA
Aeterna Zentaris AEZS	2.19 M	-	5.93 %	$ 314 M	Canada
BeiGene, Ltd. BGNE	214 M	-	0.49 %	$ 251 B	Cayman-islands
Bicycle Therapeutics plc BCYC	2.96 M	$ 3.9	0.24 %	$ 270 M	Britain
Beam Therapeutics BEAM	6.66 M	$ 26.75	0.91 %	$ 2.65 B	USA
AIkido Pharma AIKI	957 K	-	1.93 %	$ 17.4 M	USA
Aeglea BioTherapeutics AGLE	517 K	-	-	$ 1.01 B	USA
BioMarin Pharmaceutical BMRN	1.37 M	$ 67.36	0.99 %	$ 12.9 B	USA